Emma Reeve, the chair of Editas’ board, is also resigning, to be replaced by Jessica Hopfield, Ph.D., the company explained ...

Editas plans to lay off 65% of its staff — around 180 employees — as it shelves its lead gene-editing program for sickle cell ...

Editas Medicine pivots to in vivo gene editing, extends cash runway to 2027, but faces investor caution amid unclear proof-of ...

Adds analysts views. Editas Medicine (NASDAQ:EDIT) plans to slash around 180 jobs, or approximately 65% of its workforce, ...

A Cambridge-based biotechnology company announced Thursday its plans to lay off about 65% of its workforce over the next ...

Shares of Editas Medicine EDIT plunged 23.8% on Dec. 13 after it announced a strategic decision to end the development of its ...

Stifel Nicolaus cut shares of Editas Medicine (NASDAQ:EDIT – Free Report) from a buy rating to a hold rating in a report ...

Editas Medicine said Thursday afternoon it will lay off 65% of its staff — around 180 employees — as it shelves its lead gene-editing program for sickle cell disease and shifts focus.

Editas Medicine (NASDAQ:EDIT – Get Free Report) had its price target cut by analysts at Robert W. Baird from $10.00 to $8.00 ...

Editas Medicine Inc. (NASDAQ:EDIT) announced a strategic realignment to focus on in vivo gene editing. In vivo refers to ...

Evercore ISI analyst Liisa Bayko lowered the firm’s price target on Editas Medicine (EDIT) to $5 from $7 and keeps an Outperform rating on the ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $8.08, a high estimate of $13.00, ...